<DOC>
	<DOCNO>NCT01365208</DOCNO>
	<brief_summary>The combination pEBV DNA ( half-life ) PET-CT follow 1 course chemotherapy allow early detection drug response advance NPC RECIST method , patient previously untreated advanced NPC receive platinum-based chemotherapy . This study also determine new method predict survival patient . This study may far-reaching impact drug development NPC may offer optimal way evaluate drug efficacy clinical trial also clinical management .</brief_summary>
	<brief_title>New Approach Assessing Drug Response Treatment Nasopharyngeal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>undergo chemotherapy one follow setting : 1 . Setting 1 : Neoadjuvant chemotherapy prior cheomRT 2 . Setting 2 : Palliative chemotherapy Chemonaive patient 3 . Setting 3 : Palliative chemotherapy previously treat patient ( i.e . 2nd line 3rd line chemo ) Age &gt; = 18 year ( ECOG ) performance status 02 detectable level pEBV DNA baseline measurable tumor site RECIST criterion adequate bone marrow , renal hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>